Compare Moderna, Inc. (MRNA) vs TKO Group Holdings Inc (TKO) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

TKO trades at $182.79, down 1.26% on the day, with a bearish technical signal from moving averages. The stock shows strong analyst support with 89% buy ratings and a consensus price target of $228.40. Recent financials indicate revenue growth to $5.1B in 2026 with a net income margin of 4.47%, though valuation ratios like a P/E of 67.95 appear elevated. Key developments include a completed $800 million share repurchase and strong UFC event viewership.

The outlook for TKO is positive based on robust analyst consensus and expanding monetization from media deals, but risks include high valuation and recent insider selling. Earnings momentum needs to justify premium multiples, with the next quarterly report on August 3, 2026, critical for confirming growth trajectory.